Overcoming Tumor Resistance in Targeted Radiotherapy Through High-Affinity & Tumor-Specific Targeting to Improve Therapeutic Efficacy
- Identifying mechanisms of resistance that allow tumors to evade damage from radioligand therapies
- Optimizing target affinity and specificity to ensure radiopharmaceuticals bind exclusively to tumor cells and persist until therapeutic effect is achieved
- Exploring novel tumor-specific antigens, including oncofetal and developmentally restricted proteins, to minimize off-target binding and improve efficacy